Rhythm Pharmaceuticals’ Phase 3 EMANATE trial falls short of primary goals

The study included four independent genetic substudies targeting obesity caused by heterozygous variants in the POMC/PCSK1, LEPR, SRC1 (NCOA1), and SH2B1 genes

Pfizer reports breakthrough in advanced prostate cancer with TALZENNA Plus XTANDI

The study hit its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) compared to placebo plus XTANDI

Glenmark Pharmaceuticals USA launches authorized generic of Savella tablets

Glenmark's Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg is the authorized generic to Savella Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg

Eli Lilly’s experimental drug Retatrutide shows major breakthrough in Type 2 diabetes trial

Pfizer drug candidate shows strong results in tough breast cancer study

The drug also showed a manageable safety profile, with just 6.4% of patients stopping treatment due to side effects. No new safety concerns emerged

DrStore partners with TatvaCare to revolutionize diabetes & metabolic care in India

Alcon walks away from LENSAR deal after regulatory roadblock

At the center of the collapse is opposition from the Federal Trade Commission

Trial milestone sparks hope for first long-term gastroparesis treatment

The Phase 2 envisionGI study is testing deudomperidone, an experimental drug aimed at treating idiopathic gastroparesis

Zydus and Torrent Pharma to co-market Semaglutide injection in India

Zydus has developed an innovative formulation of Semaglutide Injection in a prefilled cartridge administered using a reusable patient-friendly pen device

Strides acquires generic brands from Sandoz to boost Africa business

The initial consideration for the transaction is US$ 12 million